The coronavirus 2019 (COVID-19) pandemic has disproportionately impacted lesbian, gay, bisexual, transgender, queer (LGBTQ+) people. Despite developing safe and effective COVID-19 vaccines, LGBTQ+ communities still faces challenges due to inequitable access and vaccine hesitancy. Vaccine hesitancy is a delay in the acceptance or refusal of vaccines despite the availability of vaccination services. Various studies have explored and tried to address factors influencing vaccine hesitancy. However, the LGBTQ+ population remains under- and misrepresented in many of these studies. According to the few studies that have focused on the LGBTQ+ population, several factors influencing vaccine hesitancy have been identified, with the most common factors in studies being concern about vaccine safety, vaccine efficacy, and history of bad experiences with healthcare providers. In order to rebuild the confidence of LGBTQ+ people in vaccines, governments, healthcare policymakers, and healthcare providers need to start by acknowledging, and then resolving, these disparities; building trust; dismantling systemic suppression and discrimination; and prioritizing the inclusion of LGBTQ+ people in research studies and public health policies.

The novel coronavirus (COVID-19) has become a cause for global concern. Apart from a multitude of symptoms, the virus is known for its ability to cause loss of taste and smell that can be irreversible in a few cases. In fact, even after recovery, post-covid syndrome can still lead to devastating outcomes, specifically with reference to loss of smell and taste. A number of mechanisms that have been postulated include receptor-mediated uptake, increased inflammation, transneuronal migration, and direct damage to the olfactory pathway. Considering how important these two senses are, many psychological, social, and emotional repercussions can be expected. These repercussions include lowering of self-esteem and developmental of mental health issues. Long-term altered taste sensation can also lead to the development of unhealthy eating habits that can result in increasing risk for diabetes and hypertension. A few solutions have been investigated for treating these chemosensory dysfunctions, such as olfactory training, corticosteroids, theophylline and acupuncture. Although the results have been promising but a new modality, virtual reality, requires more in-depth exploration because it targets not only the dysfunction but also the mental health issues being experienced. It is important that affected individuals be provided with strong emotional and family support. Additionally, physicians can help the patients through support groups, cognitive behavioural therapy, olfactory, and virtual reality training.

This article has been retracted due to the unknown origin of the data, lack of verified IRB approval, and purchased authorships. While not listed as an author, it was discovered that Rahil Barkat wrote and coordinated the submission of this article. Mr. Barkat was involved in data theft and misuse in two recently published Cureus articles, which have since been retracted.

Therapeutic effects of albendazole on kidney functions and urinary excretion of florfenicol was determined in goats. After restraining the animals, 600 mg dose of florfenicol was administered intramuscularly. Blood and urine samples were collected, at different time intervals, post-medication. After a washout period of 7 days, florfenicol was administrated along with a 150 mg dose of albendazole. Blood and urine samples were collected at similar time intervals as done previously. Serum was separated by centrifugation and both serum and urine samples were stored at -20ºC until analysis. Drug concentration in samples was determined by using HPLC method. Endogenous creatinine is used as an index of GFR (glomerular filtration rate) and was estimated both in serum and urine samples. Concentrations of drug and creatinine were used to calculate the renal clearance and urinary excretion. Calculated Mean ± SE of renal clearance of florfenicol was 3.32 ± 0.60 and 3.90 ± 0.52 ml/min/kg when given alone and along with albendazole respectively. Influence of serum concentration, diuresis and urinary pH on renal clearance was determined by least square regression/ correlation analysis. Mean ± SEM of urinary excretion expressed as cumulative percent of dose excreted in the urine of goats was 35.81 ± 2.47 and 37.48 ± 2.60, when florfenicol was given alone and along with albendazole respectively. Conclusion and Results were analyzed by student "t" test and it is concluded that there is significant drug-drug interaction between florfenicol and albendazole.

No abstract